Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40

Vaccine

Volumn 26, Issue 5, 2008, Pages 697-705

  Ruybal, Paula ^a   Gravisaco, María José ^a   Barcala, Virna ^b   Escalada, Ana ^c   Sciullo, Paula Di ^a   Waldner, Claudia ^a   Mongini, Claudia ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^c CITOMED   (Argentina)

Author keywords

CD40; CD40L; CD80; Costimulatory molecules; Gene therapy; T cell lymphoma

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; T LYMPHOCYTE RECEPTOR;

ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD40; ANTIGENS, CD80; CANCER VACCINES; CD40 LIGAND; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; GRAFT REJECTION; LYMPHOCYTE ACTIVATION; LYMPHOMA, T-CELL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 38049030280     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.041     Document Type: Article

References (40)

1. Liu Y., and Linsley P.S. Costimulation of T cell growth. Curr Opin Immunol 4 (1992) 265-270
2. Gimmi C.D., Freeman G.J., Gribben J.G., Gray G., and Nadler L.M. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 11 (1993) 6586-6590
3. Chen L. Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol Today 19 (1998) 27-30
4. Bennet S.R.M., Carbone F.R., Karamalis F., Flavell r.A., Miller J.F.A.P., and Heath w.R. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature 393 (1998) 478-480
5. Schoenberger S.P., Toes R.E., Van der Voort E.I., Offringa R., and Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 (1998) 480-483
6. Grewal S., and Flavell R. A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol Today 17 (1996) 410-414
7. Foy T.M., Aruffo A., Bajorath J., Buhlmann J.E., and Noelle R.J. Immune regulation by CD40 and its ligand gp39. Annu Rev Immunol 14 (1996) 591-617
8. Buhtoiarov I.N., Lum H., Berke G., Paulnock D.M., Sondel P.M., and Rakhmilevich A.L. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol 174 (2005) 6013-6022
9. Turner J.G., Rakhmilevich A.L., Burdelya L., Neal Z., Imboden M., Sondel P.M., et al. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NKcells. J Immunol 166 (2001) 89-94
10. June C.H., Bluestone J.A., Nadler L.M., and Thompson C.B. The B7 and CD28 receptor families. Immunol Today 15 (1994) 321-331
11. Hurwitz A.A., Yu T.F., Leach D.R., and Allison J.P. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 95 (1998) 10067-10071
12. Hurwitz A.A., Townsend S.E., Yu T.F., Wallin J.A., and Allison J.P. Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma. Int J Cancer 77 (1998) 107-113
13. Mongini C., Waldner C., Roig I., and Hajos S. Growth characteristics of a murine T-cell leukemia in suspension culture. In Vitro Cell Dev Biol 127 (1991) 523-524
14. Mongini C., Ruybal P., Gravisaco M.J., Croci M., Sanchez Lockhart M., Fabris V., et al. Characterization of the immunophenotipe and the metastatic properties of a murine T-lymphoma cell line. Unexpected expression of cytoplasmatic CD4. In Vitro Cell Dev Biol 37 (2001) 499-504
15. Ruybal P., Gravisaco M.J., Barcala V., Escalada A., Cremaschi G., Taboga O., et al. Transgene expression enhancement in T-lymphoma cell lines. Int Immunopharmacol 5 (2005) 1685-1692
16. Capozzo A.V., Cuberos L., Levine M.M., and Pasetti M.F. Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers. Infect Immun 72 (2004) 4637-4646
17. Gravisaco M.J., Mongini C., Alvarez E., Ruybal P., Escalada A., Sanchez-Lockhart M., et al. IL-2, IL-10, IL-15 and TNF are key regulators of murine T-cell lymphoma growth. Int J Mol Med 12 (2003) 627-632
18. Mongini C., Sanchez Lockhart M., Waldner C.I., Alvarez E.M., Gravisaco M.J., Roig M.I., et al. Enhancement of anti-tumor immunity in syngeneic mice after MHC class II gene transfection. Br J Cancer 74 (1996) 258-263
19. Tutt A.L., O'Brien L., Hussain A., Crowther G.R., French R.R., and Glennie M.J. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 168 (2002) 2720-2728
20. French R.R., Chan H.T., Tutt A.L., and Glennie M.J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5 (1999) 548-553
21. Todryk S.M., Tutt A.L., Green M.H., Smallwood J.A., Halanek N., and Dalgleish A.G. Glennie MJCD40 ligation in immunotherapy of solid tumours. J Immunol Methods 248 (2001) 139-147
22. Esche C., Gambotto A., Satoh Y., Gerein V., Robbins P.D., Watkins S.C., et al. CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. Eur J Immunol 29 (1999) 2148-2155
23. Peter I., Nawrath M., Kamarashev J., Odermatt B., Mezzacasa A., and Hemmi S. Immunotherapy for murine K1735 melanoma: combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators. Cancer Gene Ther 9 (2002) 597-605
24. Alexandroff A.B., Jackson A.M., Paterson T., Haley J.L., Ross J.A., Longo D.L., et al. Role for CD40-CD40 ligand interactions in the immune response to solid tumors. Mol Immunol 37 (2000) 515-526
25. Kato K., Cantwell M.J., Sharma S., and Kipps T.J. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 101 (1998) 1133-1141
26. Dotti G., Savoldo B., Takahashi S., Goltsova T., Brown M., Rill D., et al. Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells: a model for immunotherapy. Exp Hematol 29 (2001) 952-961
27. Noguchi M., Imaizumi K., Kawabe T., Wakayama H., Horio Y., Sekido Y., et al. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-γ gene into lung cancer. Cancer Gene Ther 8 (2001) 421-429
28. Costello R.T., and Gastaut J.A. What is the real role of CD40 in cancer immunotherapy?. Immunol Today 20 (1999) 488-493
29. Townsend S.E., and Allison J.P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259 (1993) 368-370
30. Gajewski T.F. B7. 1 but not B7. 2 efficietly costimulates CD8+ T cells in P815 tumor system in vitro. J Immunol 156 (1996) 465-472
31. Bluestone J.A. Is CTLA-4 a master switch for peripheral T cell tolerance?. J Immunol 158 (1997) 1989-1993
32. Nakajima A., Kodama T., Morimoto S., Azuma M., Takeda K., Oshima H., et al. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J Immunol 161 (1998) 1901-1907
33. Wendtner C.M., Nolte A., Mangold E., Buhmann R., Maass G., Chiorini J.A., et al. Gene transfer of costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Ther 4 (1997) 726-735
34. Ramarathinam L., Castle M., Wu Y., and Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment and effector function of antitumor T cells. J Exp Med 179 (1994) 1205-1214
35. Geldhof A.B., Raes G., Bakkus M., Devos S., Thielemans K., and De Baetselier P. Expression of B7.1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res 55 (1995) 2730-2733
36. Geldhof A.B., Moser M., Lespagnard L., Thielemans K., and De Baetselier P. Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood 91 (1998) 196-206
37. Chong H., Hutchinson G., Hart I.R., and Vile R.G. Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell dependent local anti-tumor response, but induces T-cell-dependent systemic immunity only against B7-expressing tumours. Br J Cancer 78 (1998) 1043-1050
38. Yeh K.Y., Pulaski B.A., Woods M.L., McAdam A.J., Gaspari A.A., Frelinger J.G., et al. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of poorly immunogenic murine carcinoma. Cell Immunol 165 (1995) 217-224
39. Cheung J.C., Koh C.Y., Gordon B.E., Wilder J.A., and Yuan D. The mechanism of activation of NK-cell IFNγ production by ligation of CD28. Mol Immunol 36 (1999) 361-372
40. Hodge J.W., Sabzevari H., Yafal A.G., Gritz L., Lorenz M.G., and Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 59 (1999) 5800-5807